ORIGINAL ARTICLE

¹ Department of Neonatology, Kaplan Medical Center, Rehovot, Hadassah Medical School, Hebrew University, Jerusalem, Israel
² Women and Children’s Health Research Unit, Gertner Institute, Sheba Medical Center, Tel Hashomer, Israel

Correspondence to:
Correspondence to:
E S Shinwell
Department of Neonatology, Kaplan Medical Center, Rehovot 76100, Israel;eric_s{at}clalit.org.il

Objective: To study the association between reduced use of postnatal steroids for bronchopulmonary dysplasia (BPD) in very low birthweight (VLBW) infants and oxygen (O₂)-dependency at 28 days of age and at 36 weeks postmenstrual age.

Design: Large national database study.

Setting: The Israel National VLBW Neonatal Database.

Patients: The sample included infants born between 1997 and 2004, of gestational age 24–32 weeks, who required mechanical ventilation or O₂ therapy. Four time periods were compared: 1997–8 (era 1, peak use), 1999–2000 (era 2, intermediate), 2001–2 (era 3, expected reduction) and 2003–4 (era 4, lowest). The outcome variable "oxygen dependency" was based on clinical criteria. Multivariate regression models were used to account for confounding variables.

Results: Steroid use fell significantly from 23.5% in 1997–8 to 11% in 2003–4 (p<0.005). After adjustment for relevant confounding variables, the odds ratio for O₂ therapy at 28 days in era 4 versus era 1 was 1.75, 95% confidence interval (CI) 1.47 to 2.09 and 1.41, 95% CI 1.15 to 1.73 at 36 weeks postmenstrual age. The mean duration of O₂ therapy increased from 25.3 days (95% CI 23.3 to 26.3) in era 1, to 28.0 days (95% CI 26.6 to 29.4) in era 4. Survival increased from 78.5% in era 1 to 81.6% in era 4 (p<0.005).

Conclusions: The use of steroids has fallen considerably since the awareness of the adverse effects of this treatment. This change has been temporally associated with increased O₂ dependency at 28 days of age and at 36 weeks postmenstrual age. The prolongation of O₂ therapy was modest in degree.

Abbreviations: BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; PMA, postmenstrual age; VLBW, very low birthweight

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Fantoms

Ben Stenson
Arch. Dis. Child. Fetal Neonatal Ed. 2007 92: F1. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Wilson-Costello, D., Walsh, M. C., Langer, J. C., Guillet, R., Laptook, A. R., Stoll, B. J., Shankaran, S., Finer, N. N., Van Meurs, K. P., Engle, W. A., Das, A., for the Eunice Kennedy Shriver National Institute, (2009). Impact of Postnatal Corticosteroid Use on Neurodevelopment at 18 to 22 Months' Adjusted Age: Effects of Dose, Timing, and Risk of Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants. Pediatrics 123: e430-e437 [Abstract] [Full Text]  
• Onland, W., Offringa, M., De Jaegere, A. P., van Kaam, A. H. (2009). Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled Trials. Pediatrics 123: 367-377 [Abstract] [Full Text]  
• Onland, W., De Jaegere, A. P., Offringa, M., van Kaam, A. H. (2008). Effects of Higher Versus Lower Dexamethasone Doses on Pulmonary and Neurodevelopmental Sequelae in Preterm Infants at Risk for Chronic Lung Disease: A Meta-analysis. Pediatrics 122: 92-101 [Abstract] [Full Text]